A2m Pharma
A2M Pharma is a spin-off from Schwarz Pharma with the aim of developing the most promising projects of Schwarz Pharma’s former R&D pipeline that was abandoned for strategic reasons following its merger with UCB. This portfolio includes projects in neurology and pain. A2M Pharma develops these projects until clinical proof of concept which will then be out-licensed or partnered. The current lead projects focus on the treatment of Parkinson’s disease and are supported by the Michael J Fox Foundation. A small molecular modulator of lipid rafts is in preclinical development as an α-synuclein aggregation inhibitor for disease modifying treatment of Parkinson’s Disease and potential for other protein aggregation disorders. The second lead project focusses on the treatment of dyskinesias and involves a NCE for transdermal delivery.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
2
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at A2m Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at A2m Pharma
1 distinct titles indexed · top 1 shown.
- 1accountant
Sign up to unlock all 1 contacts at A2m Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at A2m Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.